The Lupus Foundation of America (LFA) and its funded researchers will unveil the latest advances in patient-centered research at the American College of Rheumatology (ACR) Convergence 2025 meeting in ...

The U.S. Food and Drug Administration (FDA) has approved Gazyva® (obinutuzumab), developed by Genentech, as a treatment for adults with lupus nephritis (LN), also known as lupus-related kidney disease ...

There are multiple chapters near you. Select your preferred chapter.

A new study has found that women with systemic lupus erythematosus who have problems with memory and thinking (mild cognitive impairment, or MCI) exhibit morphological brain changes.

The Lupus Foundation of America is dedicated to improving the quality of life for all people affected by lupus through programs of research, education, and advocacy.

Use your power! Find your walk and register your team today. Fundraise We provide you with all the tools you need to fundraise for lupus research, support and education services all while earning ...

Living with lupus can affect your social, emotional, and financial wellbeing. But there are things you can do to cope with lupus and get the support you need. When you’re living with lupus, managing ...

Voices of Lupus is a living collection of personal stories that tell the serious and devastating health effects of lupus, while providing hope and inspiration for all lupus warriors fighting this ...

In a new study, researchers found people with clinically active systemic lupus erythematosus (SLE) disease on standard of care can attain or achieve low disease activity (LLDAS) and meet the ...

AstraZeneca announced that the Phase III TULIP-SC trial of SAPHNELO (anifrolumab) for treatment of people with systemic lupus erythematosus met its primary endpoint. Trial results showed that ...

The Lupus Foundation of America (LFA) plays a vital role in shaping policies that improve the lives of people affected by lupus. Led by our advocacy and government relations department, we work with ...